Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant Mycobacterium Tuberculosis Fusion Protein (D-EC)
- Development stage
- Unknown
- Lead developer
- Kangweizhonghe
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Recombinant Mycobacterium Tuberculosis Fusion Protein (D-EC) is a recombinant protein subunit vaccine candidate developed by Kangweizhonghe for the prevention or treatment of tuberculosis. The drug consists of a fusion protein incorporating the ESAT-6 (6 kDa early secretory antigenic target) and CFP-10 (10 kDa culture filtrate protein) antigens of *Mycobacterium tuberculosis*. These antigens are absent in the BCG vaccine strain and most non-tuberculous mycobacteria, making them highly specific targets for inducing a T-cell mediated immune response. The 'D-EC' construct is designed to elicit protective immunity or serve as an immunotherapeutic agent by stimulating the host's immune system to recognize and combat the pathogen. It is currently in Phase 2 clinical trials in China.
- Other names
- 重组结核杆菌融合蛋白Recombinant Mycobacterium Tuberculosis Fusion Protein D-EC
02
Targets
CFP-10 (Culture filtrate protein 10)ESAT-6 (Early secretory antigenic target 6)
Beyond the preview
Go deeper on Recombinant Mycobacterium Tuberculosis Fusion Protein (D-EC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinant Mycobacterium Tuberculosis Fusion Protein (D-EC).